KNSA Valuation

Kiniksa Pharmaceuticals International PLC

Add to Watchlist

Advanced Chart

38.370

-0.26(-0.673%)1D

KNSA Relative Valuation

KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KNSA is overvalued; if below, it's undervalued.

Historical Valuation

Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Fair zone, suggesting that its current forward PS ratio of 38.63 is considered Fairly compared with the five-year average of -290.83. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：37.80

Fair

20.46

Trailing

Forward

14.96

EV/EBITDA

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBITDA of 14.96. The 5-year average EV/EBITDA is -27.82. The thresholds are as follows: Strongly Undervalued below -329.65, Undervalued between -329.65 and -178.74, Fairly Valued between 123.09 and -178.74, Overvalued between 123.09 and 274.01, and Strongly Overvalued above 274.01. The current Forward EV/EBITDA of 14.96 falls within the Historic Trend Line -Fairly Valued range.

20.57

EV/EBIT

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBIT of 20.57. The 5-year average EV/EBIT is 0.50. The thresholds are as follows: Strongly Undervalued below -77.19, Undervalued between -77.19 and -38.34, Fairly Valued between 39.34 and -38.34, Overvalued between 39.34 and 78.19, and Strongly Overvalued above 78.19. The current Forward EV/EBIT of 20.57 falls within the Historic Trend Line -Fairly Valued range.

38.37

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current PS of 38.37. The 5-year average PS is 15.74. The thresholds are as follows: Strongly Undervalued below -77.88, Undervalued between -77.88 and -31.07, Fairly Valued between 62.55 and -31.07, Overvalued between 62.55 and 109.36, and Strongly Overvalued above 109.36. The current Forward PS of 38.37 falls within the Historic Trend Line -Fairly Valued range.

-140.25

P/OCF

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/OCF of -140.25. The 5-year average P/OCF is 226.50. The thresholds are as follows: Strongly Undervalued below -1994.04, Undervalued between -1994.04 and -883.77, Fairly Valued between 1336.77 and -883.77, Overvalued between 1336.77 and 2447.04, and Strongly Overvalued above 2447.04. The current Forward P/OCF of -140.25 falls within the Historic Trend Line -Fairly Valued range.

32.79

P/FCF

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/FCF of 32.79. The 5-year average P/FCF is -34.89. The thresholds are as follows: Strongly Undervalued below -362.80, Undervalued between -362.80 and -198.84, Fairly Valued between 129.07 and -198.84, Overvalued between 129.07 and 293.02, and Strongly Overvalued above 293.02. The current Forward P/FCF of 32.79 falls within the Historic Trend Line -Fairly Valued range.

Kiniksa Pharmaceuticals International PLC (KNSA) has a current Price-to-Book (P/B) ratio of 5.44. Compared to its 3-year average P/B ratio of 3.34 , the current P/B ratio is approximately 63.00% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about 50.98% higher. Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.67%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.83% , the current FCF yield is about -100.00% lower.

5.41

P/B

Median3y

3.34

Median5y

3.60

3.58

FCF Yield

Median3y

1.67

Median5y

-4.83

Competitors Valuation Multiple

The average P/S ratio for KNSA's competitors is 29.94, providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of 38.63, which is 29.01% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KNSA.O

Kiniksa Pharmaceuticals International PLC

IDEAYA Biosciences Inc

29.85

2.65B

FOLD.O

Amicus Therapeutics Inc

Apellis Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc

68.09

146.68%

2.90B

Performance Decomposition

Market capitalization of KNSA increased by 73.78% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 27.15 to 82.19.

The secondary factor is the Revenue Growth, contributed 61.17%to the performance.

Overall, the performance of KNSA in the past 1 year is driven by P/E Change. Which is more unsustainable.

61.17%

112.21M → 180.86M

Revenue Growth

-190.10%

-11.31 → 10.19

Margin Expansion

202.71%

27.15 → 82.19

P/E Change

73.78%